by Rod Raynovich | Jun 22, 2011 | BIOgraph
Last December we reviewed three low market cap diagnostic stocks that had product revenue, deal or news potential and value. All are up from our last review and Immucell(ICCC $6.97) has appreciated 100% and still has a market cap of only $20M.Immucell is focused in...
by Rod Raynovich | Jun 21, 2011 | 2024-25 Life Science Portfolios, BIOgraph
The market touched the March lows last Friday , down for the year, and buyers swarmed in.Biotechs were strong yesterday buffering tech weakness and today the baton was passed to several sectors with a broad rally especially with NASDAQ up 2.23%. The NASDAQ-100 qqq...
by Rod Raynovich | Jun 20, 2011 | 2024-25 Life Science Portfolios, BIOgraph
NASDAQ stocks rallied today just off March 2011 QQQ bottoms led by large cap biotech stocks.The NASDAQ 100 is up 0.6% led by Biogen Idec(BIIB) up 4.26%, Celgene (CELG) up 3.27%, and Gilead (GILD) up 1.5%.The rally would be stronger were it not for weak tech stocks...
by Rod Raynovich | Jun 17, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Busy Day Today -Overall a Lot of Green Screen The diagnostics and tools sector has seen resilience over the past 30 days as the market corrected 7% or more.Bellwether large cap tools stocks with revenue growth such as ILMN,NEOG, TMO have held up well helped by M&A...
by Rod Raynovich | Jun 15, 2011 | BIOgraph, Macro
Europe debt woes, riots in Greece and a 3% CPI increase for a 12 month period spooked investors. All sectors sold off today with major indices down: NASDAQ off 1.77%,Dow off 1.5%,S&P off 1.7%. Energy, materials, technology and financials were weakest, and all down...
by Rod Raynovich | Jun 14, 2011 | BIOgraph
The market rallied today with the NASDAQ up 1.48 % and the S&P up 1.26%. The leading sectors today were capital goods , materials and energy. Biotechs overall were up only 0.8% but were much better even though our mid-cap index was up only 0.49%. Within the Rayno...
by Rod Raynovich | Jun 13, 2011 | BIOgraph
Following up on the previous post we can review selected small and mid-stocks participating in the ASCO Conference look at performance over 3 months from March 14 to June 13 including a 7% correction in the market overall. Most biotech stocks peaked in Q2 2011. See...
by Rod Raynovich | Jun 13, 2011 | BIOgraph
Despite an ASCO “sell on the news” and a severe Q2 correction some mid and small cap cancer related stocks are still up although off their highs. See commentary and news from earlier posts. More on these and others later:
by Rod Raynovich | Jun 10, 2011 | 2024-25 Life Science Portfolios, BIOgraph
All major indices and sectors sold off today making it 7 bad days out of 8 and a 6.37% correction in the S&P 500 over 30 days. The NASDAQ is now down 7.94% since May 11. Remember “sell in May and go away” ? Things were not much better in biotech-land...
by Rod Raynovich | Jun 9, 2011 | BIOgraph
The market rallied on the seventh day after six days of losses but we still have a few hours to go. The Dow is up 0.96% and the NAZ is up 0.64%.Life Science stocks are strong overall with mid-caps up 0.75%. Diagnostics and tools are the strongest sector and within...
